BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected in 2013. Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels. Johnson & Johnson ( JNJ) Drug/indication: Canagliflozin for diabetes. FDA advisory panel: Jan. 10 Approval decision date: March 29 Theravance ( THRX) Drug/indication: Vibativ for hospital acquired pneumonia Approval decision date: Jan. 11 Santarus ( SNTS) Drug/indication: Uceris for ulcerative colitis Approval decision date: Jan. 16 NuPathe ( PATH) Drug/indication: Zelrix for migraine Approval decision date: Jan. 17, 2013 Impax Labs ( IPXL) Drug/indication: IPX066 for Parkinson's disease Approval decision date: Jan. 21 Hyperion Therapeutics ( HPTX) Drug/indication: Ravicti for urea cycle disorder Approval decision date: Jan. 23 Sanofi ( SNY) and Isis Pharmaceuticals ( ISIS) Drug/indication: Kynamro for dyslipidemia/hypercholesterolemia Approval decision date: Jan. 29, 2013 Raptor Pharmaceutical ( RPTP) Drug/indication: RP103 for cystinosis Approval decision date: Jan. 30, 2013 Hemispherx Biopharma ( HEB) Drug/indication: Ampligen for chronic fatigue syndrome Approval decision date: Feb. 1, 2013 Celgene ( CELG) Drug/indication: Pomalidomide for multiple myeloma Approval decision date: Feb. 8, 2013 Dynavax ( DVAX) Drug/indication: Heplisav for hepatitis B prevention Approval decision date: Feb. 22, 2013 Roche ( RHHBY) and Immunogen ( IMGN) Drug/indication: T-DM1 for breast cancer Approval decision date Feb. 26 Zogenix ( ZGNX) Drug/indication: Zohydro for chronic pain Approval decision date: March 1, 2013 Depomed ( DEPO) Drug/indication: Serada for menopause FDA advisory panel: March 4 Approval decision date: May 31 Bristol-Myers Squibb ( BMY) Drug/indication: Eliquis for blood clot prevention Approval decision date: March 15 A.P. Pharma ( APPA) Drug/indication: APF530 for chemotherapy induced nausea Approval decision date: March 27 Biogen Idec ( BIIB) Drug/indication: BG-12 for multiple sclerosis Approval decision date: March 28 MAP Pharma ( MAPP) Drug/indication: Levadex for migraine Approval decision date: April 15 Sucampo Pharmaceuticals ( SCMP) Drug/indication: Amitzia for opioid-induced constipation Approval decision date: April 26 Navidea Biopharmaceuticals ( NAVB) Drug/indication: Lymphoseek, a radioactive tracing agent for lymph node mapping Approval decision date: April 30 GlaxoSmithKline ( GSK) Drug/indication: Dabrefenib for melanoma FDA advisory panel: June 3 Delcath Systems ( DCTH) Drug/indication: ChemoSat for liver metastases due to ocular melanoma Approval decision date: June 14 AVEO Pharmaceuticals ( AVEO) Drug/indication: Tivozanib for kidney cancer Approval decision date: July 28 Companies with drugs filed to FDA but no assigned approval decision dates: Auxillium Pharmaceuticals ( AUXL): Xiaflex for Peyronie's disease Bayer and Algeta: Alpharadin for prostate cancer Antares Pharma ( ATRS): Otrexup for rheumatoid arthritis GlaxoSmithKline: Dolutegravir for HIV Sources: Company reports, TheStreet research, BioMedTracker --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.